Mason Street Advisors, LLC Exelixis, Inc. Transaction History

Mason Street Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $3.4 Million - $4.18 Million	-165,692 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$18.39 - $24.8 $5,756 - $7,762	313 Added 0.19%	165,692 $3.33 Million
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $55,168 - $71,902	-2,669 Reduced 1.59%	165,379 $4.04 Million
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $105,936 - $176,475	6,436 Added 3.98%	168,048 $3.99 Million
Q4 2019 Feb 19, 2020	BUY	$15.15 - $18.89 $41,829 - $52,155	2,761 Added 1.74%	161,612 $2.85 Million
Q3 2019 Nov 05, 2019	SELL	$17.68 - $22.65 $35,306 - $45,232	-1,997 Reduced 1.24%	158,851 $2.81 Million
Q2 2019 Aug 12, 2019	BUY	$18.93 - $24.75 $23,605 - $30,863	1,247 Added 0.78%	160,848 $3.44 Million
Q1 2019 May 07, 2019	BUY	$19.6 - $24.76 $58,662 - $74,106	2,993 Added 1.91%	159,601 $3.8 Million
Q4 2018 Feb 13, 2019	BUY	$13.65 - $21.8 $48,252 - $77,063	3,535 Added 2.31%	156,608 $3.08 Million
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $133,355 - $188,227	8,403 Added 5.81%	153,073 $2.71 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $2.69 Million - $3.25 Million	144,670 New	144,670 $3.11 Million

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Mason Street Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Mason Street Advisors, LLC with notifications on news.